Independent. No tobacco money. No corporate fluff.THU, OCT 8

PouchDaily

The daily pulse of the nicotine pouch market

Science
US

The biggest evidence review on nicotine pouches just got bigger — 135 studies, one clear bottom line

An updated Georgetown-led scoping review adds 73 studies to its evidence base: pouches are considerably less toxic than cigarettes, higher-strength pouches deliver more nicotine than a cigarette, and the quit evidence remains thin.

PouchDaily Desk·
researchscoping reviewGeorgetownNicotine & Tobacco Researchtoxicityyouth use

A team led by Georgetown's Lombardi Comprehensive Cancer Center has published the first major update to its nicotine-pouch evidence review, and the headline finding is blunt: oral nicotine pouches are "considerably less toxic than cigarettes, but their long-term health impacts remain understudied." The updated scoping review ran in Nicotine & Tobacco Research on 6 September, led by Nargiz Travis with veteran tobacco researchers Kenneth Warner, Jamie Hartmann-Boyce and Maciej Goniewicz as co-authors.

The team searched six databases for research published through 30 September 2025, adding 73 new studies to the 62 from their 2024 review — an evidence base of 135 studies covering product contents, toxicity, use patterns, perceptions and marketing.

What the evidence now says

Toxicity: Laboratory studies and exposure data both point the same way. One US survey analysis found pouch-only users had lower levels of cadmium, uranium and lead than cigarette smokers — lead comparable to people who don't use tobacco at all. The caveat: that analysis was small, and much of the short-term switching evidence is limited and partly industry-funded.

Nicotine delivery: This is where the review complicates the "milder" story. Nicotine uptake scales with strength, and from about 6 mg and up, adult smokers typically absorb more nicotine from a pouch than from a cigarette. One study of 20 mg and 30 mg products found blood-pressure and arterial-stiffness effects comparable to smoking a cigarette. The authors explicitly warn against a single delivery claim covering every pouch.

Quitting: Two small pilot trials showed pouches cut cigarette consumption — in one eight-week trial, daily consumption fell by nearly half — but almost nobody switched completely. Most users end up dual-using, and the authors say evidence on pouches as a cessation aid remains insufficient.

The market: US sales more than tripled between 2021 and 2024. Adult use stayed under 1% in 2022–2023 surveys, but the National Youth Tobacco Survey recorded 1.8% of middle and high school students using pouches in 2024, up from 0.8% in 2021 — a slow rise the review flags alongside increasingly youth-appealing marketing.

Why it matters

This is the evidence base that regulators will actually read — the authors position the review as input for agencies weighing product standards and marketing rules, and it lands while the FDA reworks its pouch review process and the EU weighs the next Tobacco Products Directive. The honest summary is uncomfortable for both camps: pouches are clearly the less hazardous nicotine delivery format versus smoking, but they're not risk-free, high-strength products deserve separate scrutiny, and nobody can yet say whether they get smokers to quit or just keep them smoking while adding pouches.

The review's own limitations are worth noting: the authors didn't formally assess bias risk in each of the 135 studies, and 12 of the 73 new studies were industry-funded.

For readers comparing brands and strengths across retailers, PouchFinder lists strength levels side by side.

SOURCES